2-Acetamidophenol-d3

CAT: 0804-HY-W015600S-01Size: 1 mgDry Ice: NoHazardous: No
CAT#: HY-W015600S-01Size: 1 mg
Selected
AVAILABILITY
24/48H Stock Items & 2 to 6 Weeks non Stock Items.
Product image 1
1 / 1
Description
2-Acetamidophenol-d3 (Orthocetamol-d3) is the deuterium labeled 2-Acetamidophenol (HY-W015600) . 2-Acetamidophenol (Orthocetamol) is a regulator that targets ferroptosis and glutathione metabolic pathways, is the ortho-regioisomer of Paracetamol (HY-66005) . 2-Acetamidophenol has anti-atherosclerotic activity, and inhibiting total cholesterol (TC) and triglyceride (TG) in a zebrafish hyperlipidemia model with IC50s for 30 μM and 40 μM, respectively. 2-Acetamidophenol upregulates the expression of glutathione synthesis-related genes (such as GCLC, GCLM, GSS) and iron ion transport genes (such as FPN1, FTH), reduces the accumulation of intracellular reactive oxygen species (ROS) and ferrous ions (Fe2+), and enhances the activity of glutathione peroxidase GPX4, thereby inhibiting macrophage phagocytosis of oxidized low-density lipoprotein (ox-LDL) and foam cell formation[1][2].
CAS Number
[122258-87-1]
Product Name Alternative
Orthocetamol-d3
UNSPSC
12352005
Target
Ferroptosis; Glutathione Peroxidase; Isotope-Labeled Compounds; LDLR; Reactive Oxygen Species (ROS)
Related Pathways
Apoptosis; Immunology/Inflammation; Metabolic Enzyme/Protease; NF-κB; Others
Applications
COVID-19-immunoregulation
Field of Research
Inflammation/Immunology; Cardiovascular Disease
Smiles
OC1=C(NC(C([2H])([2H])[2H])=O)C=CC=C1
Molecular Formula
C8H6D3NO2
Molecular Weight
154.18
References & Citations
[1]Zang X, et al. 2-Acetamidophenol (2-AAP) Suppresses the Progression of Atherosclerosis by Alleviating Hyperlipidemia and Attenuating the Ferroptosis Pathway. Mar Drugs. 2024 Nov 13;22 (11) :513. |[2]Andrusenko I, et al. The Crystal Structure of Orthocetamol Solved by 3D Electron Diffraction. Angew Chem Int Ed Engl. 2019 Aug 5;58 (32) :10919-10922.
Shipping Conditions
Room temperature
Scientific Category
Isotope-Labeled Compounds
Clinical Information
No Development Reported
Isoform
GPX4